Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directorate Change

1st Apr 2015 07:00

RNS Number : 0819J
Carclo plc
01 April 2015
 





31 March 2015

Carclo plc ("Carclo")

 

 

Board change

 

The board announces that David Toohey has been appointed to the Carclo plc board as a non-executive director with effect from 1 April 2015.

 

David Toohey has over 30 years' experience in international business, the last 20 of which have been in medical devices and the In Vitro Diagnostics ('IVD') industry. He has been Chief Executive Officer of Syncrophi Systems Limited ("Syncrophi"), since 2012. He joined Syncrophi from Alere Inc, the global diagnostics and health management company, where he spent 11 years in senior managerial roles, latterly as President of International Business Operations. Mr. Toohey held various Executive positions at Boston Scientific Corporation, Bausch & Lomb, Inc., Digital Equipment Corp. and Mars, Inc. He has been an Independent Non-Executive Director at EKF Diagnostics Holdings plc since August 2014.

 

There are no further disclosures relating to David Toohey required under paragraph 9.6.13R of the Listing Rules.

 

Enquiries:

Carclo plc

01924 268040

Chris Malley, Chief Executive

Robert Brooksbank, Finance Director

Peel Hunt LLP

0207 418 8900

Justin Jones

Jock Maxwell Macdonald

Mike Bell

N+1 Singer

0207 496 3000

Shaun Dobson

Richard Lindley

Weber Shandwick Financial

020 7067 0700

Nick Oborne

Tom Jenkins

 

Notes to editors

Carclo plc is a public company whose shares are quoted on the London Stock Exchange.

Carclo's strategy is to develop and expand its key manufacturing assets where there remain significant further opportunities to drive value. To enhance profit margins the group has been investing in new technologies.

Approximately three fifths of revenues are currently derived from the supply of fine tolerance, injection moulded plastic components, mainly for medical products. The balance of revenue is derived mainly from the design and supply of specialised injection moulded LED based lighting systems to the low volume premium automotive industry.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAWGUMAWUPAGQG

Related Shares:

Carclo
FTSE 100 Latest
Value8,328.60
Change52.94